Students Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, PO Box 81745, Tehran, Iran.
Trials. 2020 Feb 18;21(1):201. doi: 10.1186/s13063-020-4108-7.
No conclusive treatment is available for irritable bowel disease (IBD). Adherence to a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) might alleviate clinical symptoms of IBD. However, no study has investigated the effect of low FODMAPs diet on the intestinal microbiota and inflammatory biomarkers in patients with IBD. The aim of current study is to examine the effect a low FODMAP diet on IBD symptoms, inflammation, and the intestinal microbiota in patients with ulcerative colitis.
This study is a randomized clinical trial. Thirty patients with mild to moderate ulcerative colitis will be randomly allocated to receive a low FODMAP diet (n = 15) or to continue their usual diet as control (n = 15), for 4 weeks. The quantity of intestinal microbiota including Clostridium cluster IV, Faecalibacterium prausnitzii, Rosburia spp., Lactobacillus spp., Bifidobacteria spp., Akkermansia muciniphila, Bacteroides fragilis, and Ruminococcus spp., and the Firmicutes to Bacteroidetes ratio and calprotectin and lactoferrin levels will be explored in fecal samples from patients. In addition, anthropometric measures and biochemical assessments including serum concentrations of highly sensitive-C reactive protein (hs-CRP), tumour necrosis factor-α (TNF-α) and IL-1β will be taken from patients at baseline and end of the study. The study has been registered in IRCT (IRCT20181126041763N1; registration date: 2019-01-18).
Consumption of a low-FODMAP diet might decrease systemic and intestinal inflammation, change the bacterial population in the gut, and modulate clinical symptoms in patients with ulcerative colitis. Further studies investigating the effect of such a diet on other variables, including other bacterial species and inflammatory cytokines, are required to confirm future findings of this trial.
目前对于肠易激综合征（IBD）尚无明确的治疗方法。遵循低可发酵寡糖、双糖、单糖和多元醇（FODMAPs）饮食可能会缓解 IBD 的临床症状。然而，目前尚无研究调查低 FODMAPs 饮食对 IBD 患者肠道微生物群和炎症生物标志物的影响。本研究旨在研究低 FODMAPs 饮食对溃疡性结肠炎患者 IBD 症状、炎症和肠道微生物群的影响。
这是一项随机临床试验。将 30 名轻度至中度溃疡性结肠炎患者随机分为低 FODMAPs 饮食组（n=15）或继续常规饮食作为对照组（n=15），进行为期 4 周的干预。将检测粪便样本中包括梭菌属 IV 簇、普拉梭菌、罗氏菌属、乳杆菌属、双歧杆菌属、粘蛋白阿克曼菌、脆弱拟杆菌和瘤胃球菌属在内的肠道微生物群数量，以及厚壁菌门与拟杆菌门的比值和钙卫蛋白、乳铁蛋白水平。此外，还将从患者中采集人体测量和生化评估数据，包括血清超敏 C 反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）和白细胞介素-1β（IL-1β）浓度，在基线和研究结束时进行。该研究已在 IRCT 注册（IRCT20181126041763N1；注册日期：2019-01-18）。
低 FODMAPs 饮食的摄入可能会降低全身和肠道炎症，改变肠道中的细菌种群，并调节溃疡性结肠炎患者的临床症状。需要进一步研究这种饮食对其他变量的影响，包括其他细菌种类和炎症细胞因子，以证实本试验的未来研究结果。
